Compare Stocks: NWBO, SANA, KURA, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$20.24	$16.59	$12.12 ▼ $35.34	$1.24B	2.53	840,616 shs	700,767 shs
KURA Kura Oncology	$13.25	$11.11	$7.36 ▼ $13.90	$1.18B	0.44	2.38 million shs	1.31 million shs
NWBO Northwest Biotherapeutics	$0.17	$0.18	$0.14 ▼ $0.34	$292.96M	-0.61	3.64 million shs	1.72 million shs
SANA Sana Biotechnology	$3.85	$3.63	$2.61 ▼ $6.55	$1.15B	2.12	2.46 million shs	1.24 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	0.00%	+12.26%	+27.70%	+49.81%	-15.60%
KURA Kura Oncology	0.00%	+4.66%	+38.45%	+54.79%	+61.19%
NWBO Northwest Biotherapeutics	0.00%	-10.50%	-7.57%	-15.53%	-32.82%
SANA Sana Biotechnology	0.00%	-2.04%	+9.38%	+43.12%	+30.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$20.24	$16.59	$12.12 ▼ $35.34	$1.24B	2.53	840,616 shs	700,767 shs
KURA Kura Oncology	$13.25	$11.11	$7.36 ▼ $13.90	$1.18B	0.44	2.38 million shs	1.31 million shs
NWBO Northwest Biotherapeutics	$0.17	$0.18	$0.14 ▼ $0.34	$292.96M	-0.61	3.64 million shs	1.72 million shs
SANA Sana Biotechnology	$3.85	$3.63	$2.61 ▼ $6.55	$1.15B	2.12	2.46 million shs	1.24 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	0.00%	+12.26%	+27.70%	+49.81%	-15.60%
KURA Kura Oncology	0.00%	+4.66%	+38.45%	+54.79%	+61.19%
NWBO Northwest Biotherapeutics	0.00%	-10.50%	-7.57%	-15.53%	-32.82%
SANA Sana Biotechnology	0.00%	-2.04%	+9.38%	+43.12%	+30.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	80.15% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	91.70% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	142.42% Upside

Current Analyst Ratings Breakdown

Latest NWBO, SANA, KURA, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JANX Janux Therapeutics	$10M	123.75	N/A	N/A	$15.91 per share	1.27
KURA Kura Oncology	$67.48M	17.47	N/A	N/A	$2.00 per share	6.63
NWBO Northwest Biotherapeutics	$1.38M	212.29	N/A	N/A	($0.04) per share	-4.24
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
NWBO Northwest Biotherapeutics	-$60.16M	-$18.23	N/A	N/A	N/A	-1,736.35%	N/A	-56.34%	11/12/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest NWBO, SANA, KURA, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NWBO Northwest Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.81 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JANX Janux Therapeutics	N/A	16.35	16.35
KURA Kura Oncology	0.12	4.73	4.71
NWBO Northwest Biotherapeutics	N/A	0.04	0.04
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JANX Janux Therapeutics	75.39%
KURA Kura Oncology	N/A
NWBO Northwest Biotherapeutics	0.04%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
JANX Janux Therapeutics	7.90%
KURA Kura Oncology	7.60%
NWBO Northwest Biotherapeutics	2.40%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable
NWBO Northwest Biotherapeutics	20	1.73 billion	1.68 billion	Not Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable

NWBO, SANA, KURA, and JANX Headlines

Recent News About These Companies

Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

September 3, 2026 | marketbeat.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

As US.-China biotech race heats up, Seattle makes its case to DC

August 27, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7% Following Analyst Upgrade

August 27, 2026 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention

August 21, 2026 | kalkinemedia.comK

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

August 21, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?

August 20, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?

August 19, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)

August 19, 2026 | theglobeandmail.com

Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA

August 18, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter?

August 15, 2026 | kalkinemedia.comK

Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

August 14, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

August 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, SANA, KURA, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

$20.24 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Kura Oncology NASDAQ:KURA

$13.25 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.17 0.00 (0.00%)

As of 09/4/2026 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Sana Biotechnology NASDAQ:SANA

$3.85 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NWBO, SANA, KURA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NWBO, SANA, KURA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NWBO, SANA, KURA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, SANA, KURA, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

Northwest Biotherapeutics OTCMKTS:NWBO

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NWBO, SANA, KURA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NWBO, SANA, KURA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NWBO, SANA, KURA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, SANA, KURA, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

Northwest Biotherapeutics OTCMKTS:NWBO

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools